Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
Authors
Johnson, PFederico, M
Kirkwood, A
Fosså, A
Berkahn, L
Carella, A
d'Amore, F
Enblad, G
Franceschetto, A
Fulham, M
Luminari, S
O'Doherty, M
Patrick, P
Roberts, T
Sidra, G
Stevens, L
Smith, P
Trotman, J
Viney, Z
Radford, John A
Barrington, S
Affiliation
Cancer Research UK Centre, University of Southampton, SouthamptonIssue Date
2016
Metadata
Show full item recordAbstract
We tested interim positron-emission tomography-computed tomography (PET-CT) as a measure of early response to chemotherapy in order to guide treatment for patients with advanced Hodgkin's lymphoma.Citation
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. 2016, 374 (25):2419-29 N Engl J MedJournal
The New England Journal of MedicineDOI
10.1056/NEJMoa1510093PubMed ID
27332902Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1510093
Scopus Count
Collections
Related articles
- Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.
- Authors: Ganesan P, Rajendranath R, Kannan K, Radhakrishnan V, Ganesan TS, Udupa K, Lakshmipathy KM, Mahajan V, Sundersingh S, Rajaraman S, Krishnakumar R, Sagar TG
- Issue date: 2015 Jun
- Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
- Authors: Anderson RA, Remedios R, Kirkwood AA, Patrick P, Stevens L, Clifton-Hadley L, Roberts T, Hatton C, Kalakonda N, Milligan DW, McKay P, Rowntree C, Scott FM, Johnson PWM
- Issue date: 2018 Oct
- Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
- Authors: Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, Shimoni A, Nagler A, Ben-Bassat I, Polliack A
- Issue date: 2010 Jan
- Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
- Authors: Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S
- Issue date: 2015 Apr 23
- Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
- Authors: Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A
- Issue date: 2017 Apr